Faron Pharmaceuticals Oy (LSE:FARN) EBIT : £-18.38 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy EBIT?

Faron Pharmaceuticals Oy's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was £-9.92 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was £-18.38 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Faron Pharmaceuticals Oy's annualized ROC % for the quarter that ended in Dec. 2024 was -203.99%. Faron Pharmaceuticals Oy's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -7,331.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Faron Pharmaceuticals Oy's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -9.44%.

Faron Pharmaceuticals Oy EBIT Historical Data

The historical data trend for Faron Pharmaceuticals Oy's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy EBIT Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-15.19

-17.81

-23.79

-24.83

-18.20

Faron Pharmaceuticals Oy Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT	Get a 7-Day Free Trial															-	-10.99	-13.79	-8.46	-9.92

Competitive Comparison of Faron Pharmaceuticals Oy's EBIT

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's EV-to-EBIT falls into.

Faron Pharmaceuticals Oy EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-18.38 Mil.

Faron Pharmaceuticals Oy (LSE:FARN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Faron Pharmaceuticals Oy's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-12.23 * ( 1 - 0.35% )	/	( (6.358	+	5.591)	/ 2 )
=	-12.187195	/	5.9745
=	-203.99 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30.002	-	14.783	-	( 25.364	-	max(0, 19.877	-	28.738	+	25.364	))
=	6.358

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.371	-	4.039	-	( 7.871	-	max(0, 8.424	-	9.165	+	7.871	))
=	5.591

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Faron Pharmaceuticals Oy's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-19.832	/	( ( (0.294 + max(-16.68, 0))	+	(0.247 + max(-4.116, 0)) )	/	2 )
=	-19.832	/	( ( 0.294	+	0.247 )	/	2 )
=	-19.832	/	0.2705
=	-7,331.61 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.00099999999999767)	-	(14.783	+	0	+	1.898)
=	-16.68

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.128)	-	(4.039	+	0	+	1.205)
=	-4.116

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Faron Pharmaceuticals Oy's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	-18.376	/	194.713
	=	-9.44 %

Faron Pharmaceuticals Oy EBIT Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.

Faron Pharmaceuticals Oy Headlines

No Headlines